Clinical pressrelease · April 3, 2025 · 6 min read

New drug candidate targeting synaptic resilience well tolerated in Alzheimer’s patients

Alzheimer's disease Interim data p-tau217 Phase 2 PTX-101
All stories  →
Clinical February 11, 2016

Alzheimer’s from a New Angle

Dr. Frank Longo on hope, innovation, and a radical departure…

Read release →
Corporate October 24, 2023

Targeting Endogenous Mechanisms of Brain Resilience in Alzheimer’s Disease

JPAD review frames p75NTR as a tractable resilience pathway for…

Read release →
Clinical April 3, 2025

New drug candidate targeting synaptic resilience well tolerated in Alzheimer’s patients

NIA summarizes safety and biomarker findings supporting larger LM11A-31 trials.

Read release →